Pleural
Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma
Frontiers in Cell and Developmental Biology 2022 July 1 [Link] Shichao Zhang, Shuqin Li, Ya Wei, Yu Xiong, Qin Liu, Zuquan Hu, Zhu Zeng, Fuzhou Tang, Yan Ouyang Abstract Messenger RNA vaccines are considered to be a promising strategy in cancer immunotherapy, while their application on mesothelioma is still largely uncharacterized. This study aimed to…
Read MoreMalignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow
Translational Lung Cancer Research 2022 June [Link] Ildiko Kovacs, Edina Bugyik, Katalin Dezso, Julia Tarnoki-Zach, Elod Mehes, Marton Gulyas, Andras Czirok, Elisabeth Lang, Michael Grusch, Karin Schelch, Balazs Hegedus, Ildiko Horvath, Nandor Barany, Zsolt Megyesfalvi, Anna Tisza, Zoltan Lohinai, Mir Alireza Hoda, Konrad Hoetzenecker, Francesco Pezzella, Sandor Paku, Viktoria Laszlo, Balazs Dome Abstract Background: The…
Read MoreLurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma
European Journal of Cancer 2022 July 11 [Link] Daphne W Dumoulin, Luca Cantini, Robin Cornelissen, Madelief Vink, Larissa Klaase, Kick Sloof, Nura Tebayna, Joanne M Mankor, Sara J Baart, Rudi Hendriks, Anne-Marie C Dingemans, Marcella Willemsen, Joachim G J V Aerts Abstract Purpose: Lurbinectedin is a promising new drug being investigated in pre-treated patients with…
Read MoreDoes mediastinal lymph node involvement influence the surgical outcome in malign pleural mesothelioma?
Acta Chirurgica Belgica 2022 July 15 [Link] Mehmet Ali Bedirhan, Yunus Seyrek, Volkan Yaran, Celal Buğra Sezen, Levent Cansever, Muzaffer Metin Abstract Background: This study examined the effect of metastatic mediastinal lymph node involvement on the prognosis of patients with malignant pleural mesothelioma (MPM) who underwent extrapleural pneumonectomy (EPP) or extended pleurectomy (E/P) and also…
Read MoreMolecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
Targeted Oncology 2022 July 30 [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos…
Read MorePrognostic values of preoperative C-reactive protein, albumin, and neutrophil ratios in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy
Surgical Oncology 2022 July 6 [Link] Riki Okita, Masanori Okada, Hidetoshi Inokawa, Tomoyuki Murakami, Eiji Ikeda Abstract Introduction: A preoperative validation system for predicting the clinical outcome of extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM) is required, as EPP for MPM is one of the most invasive operation types. Recently, several inflammatory and nutritional…
Read MoreSubstance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study
International Journal of Molecular Science 2022 June 30 [Link] Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann, Chris Braumann Abstract Malignant peritoneal mesothelioma is a rare tumor entity. Although cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have increased overall survival, its prognosis remains poor. Established chemotherapeutics…
Read MorePrognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma
Frontiers in Oncology 2022 June 20 [Link] Hely Ollila, Mikko I Mäyränpää, Lassi Paavolainen, Juuso Paajanen, Katja Välimäki, Eva Sutinen, Henrik Wolff, Jari Räsänen, Olli Kallioniemi, Marjukka Myllärniemi, Ilkka Ilonen, Teijo Pellinen Abstract Background: Pleural mesothelioma (MPM) is an aggressive malignancy with an average patient survival of only 10 months. Interestingly, about 5%-10% of the…
Read MoreThrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
JTO Clinical and Research Reports 2022 June 9 [Link] Takaaki Tanaka, Shoji Asakura, Kazuya Hisamatsu, Nobukazu Fujimoto Abstract A 69-year-old man presented with a pulmonary opacity at a regular medical check-up. He had been exposed to asbestos in a chemical fiber manufacturing setting. Result of positron emission tomography with computed tomography (CT) revealed fluorodeoxyglucose accumulations…
Read MoreChallenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features
Annals of Diagnostic Pathology 2022 June 30 [Link] Prakasit Sa-Ngiamwibool, Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Takahiko Kasai, Kenzo Hiroshima, Kei Kushitani, Yukio Takeshima, Kunimitsu Kawahara, Akinori Iwasaki, Kazuki Nabeshima Abstract Aim: Genomic-based ancillary assays including immunohistochemistry (IHC) for BRCA-1 associated protein-1 (BAP1) and methylthioadenosine phosphorylase (MTAP), and fluorescence in situ…
Read More